Mankind Pharma has announced the incorporation of its wholly-owned subsidiary in the Netherlands. This strategic move, effective August 13, 2026, under the name “Mankind Pharma (Netherlands) B.V.,” signifies the company’s ongoing commitment to international market expansion and strengthens its global footprint. This development follows a prior intimation on July 11, 2026, outlining the preliminary steps for this venture.
Subsidiary Incorporation in Netherlands
Mankind Pharma Limited has successfully incorporated its wholly-owned subsidiary in the Netherlands. The incorporation took place today, August 13, 2026, and the new entity will operate under the name Mankind Pharma (Netherlands) B.V. This development is a significant step in the company’s strategic international expansion initiatives.
Strategic International Expansion
The incorporation of this subsidiary follows an earlier intimation provided by the company on July 11, 2026. This move underscores Mankind Pharma’s dedication to broadening its global reach and market presence. The detailed disclosures required by the relevant listing regulations were previously furnished in the company’s intimation dated July 11, 2026.
Source: BSE
